Terug
Ook genoteerd als
JDHIF
OTC
Dagbereik
€ 6,85
€ 7,00
52-Weeksbereik
€ 3,81
€ 9,08
Volume
500
50D / 200D Gem.
€ 8,82
/
€ 7,85
Vorige Slotkoers
€ 6,85
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (627 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 4,2 | 0,3 |
| P/B | 0,4 | 2,9 |
| ROE % | 9,1 | 3,7 |
| Net Margin % | 7,3 | 3,8 |
| Rev Growth 5Y % | 23,5 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
€ 0,00
€ 0,00 – € 0,00
|
100 B | 0 |
| FY2026 |
€ 0,00
€ 0,00 – € 0,00
|
87 B | 0 |
Belangrijkste Punten
Revenue grew 23,53% annually over 5 years — strong growth
Earnings grew 25,64% over the past year
Debt/Equity of 0,01 — conservative balance sheet
Negative free cash flow of 0,0
P/E of 4,19 — trading at a low valuation
ROIC of 4,56% — low return on invested capital
Groei
Revenue Growth (5Y)
23,53%
Revenue (1Y)22,83%
Earnings (1Y)25,64%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
9,07%
ROIC4,56%
Net Margin7,32%
Op. Margin5,17%
Veiligheid
Debt / Equity
0,01
Current Ratio2,72
Interest Coverage342,21
Waardering
P/E Ratio
4,19
P/B Ratio0,36
EV/EBITDA-2,50
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 22,83% | Revenue Growth (3Y) | 15,52% |
| Earnings Growth (1Y) | 25,64% | Earnings Growth (3Y) | 56,25% |
| Revenue Growth (5Y) | 23,53% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 71,44B | Net Income (TTM) | 5,23B |
| ROE | 9,07% | ROA | 6,41% |
| Gross Margin | 24,78% | Operating Margin | 5,17% |
| Net Margin | 7,32% | Free Cash Flow (TTM) | 0,0 |
| ROIC | 4,56% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,01 | Current Ratio | 2,72 |
| Interest Coverage | 342,21 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 4,19 | P/B Ratio | 0,36 |
| P/S Ratio | 0,31 | PEG Ratio | 1,41 |
| EV/EBITDA | -2,50 | Dividend Yield | 0,00% |
| Market Cap | 21,93B | Enterprise Value | -9,25B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 71,44B | 58,16B | 53,53B | 46,74B | 30,68B |
| Net Income | 5,23B | 4,16B | 2,14B | 380,11M | -1,07B |
| EPS (Diluted) | 1,61 | 1,32 | 0,68 | 0,12 | -0,35 |
| Gross Profit | 17,70B | 13,31B | 11,87B | 9,89B | 7,20B |
| Operating Income | 3,69B | 1,48B | 630,85M | 803,11M | -857,14M |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 81,64B | 71,27B | 64,29B | 61,28B | 48,00B |
| Total Liabilities | 21,53B | 16,03B | 14,92B | 16,49B | 8,15B |
| Shareholders' Equity | 60,11B | 55,23B | 49,36B | 44,78B | 39,85B |
| Total Debt | 636,42M | 258,39M | 214,75M | 199,41M | 201,27M |
| Cash & Equivalents | 31,81B | 22,63B | 15,04B | 18,72B | 17,25B |
| Current Assets | 56,38B | 58,46B | 47,85B | 56,45B | 45,71B |
| Current Liabilities | 20,75B | 15,52B | 14,58B | 16,36B | 8,01B |
Strategiescores
This stock passed the criteria for 4 strategies
Score = fit strength (0–100)
Rank = position among all matches
Recente Activiteit
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt
Full Throttle
Mar 24, 2026